Acrivon reports 50% confirmed ORR with ACR-368 in OncoSignature-positive gynecological cancers; cash ~$234M

Acrivon Therapeutics, Inc.

Phase 2b: 50% confirmed ORR in OncoSignature-positive ovarian/endometrial (10 pts), 0% ORR in negative (16), p=0.0038.
Median duration of response not yet reached; all responders remain on treatment.
ACR-2316 dual WEE1/PKMYT1 inhibitor IND filing accelerated to Q3 2024; clinical trial expected Q4 2024.
Preliminary cash $110M at March 31; pro forma $234M after private placement, funding into H2 2026.
Initial prospective validation of AP3 platform ability to predict ACR-368 responders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.